Table 3 Multivariable analysis of factors predictive of change in prevalence (increase or decrease) of drug-drug interactions (DDIs) at 2 months compared to baseline

Male

0.76 [0.59–0.98]

.03

- Louvain

1.24 [0.87–1.74]

.22

- 1Utrecht

1.12 [0.80–1.55]

.51

- Cork

0.70 [0.47–1.02]

.06

Medical history of depression

1.69 [1.14–2.48]

.008

Medical history of atrial fibrillation

1.29 [0.99–1.67]

.05

Medical history of coronary heart disease

1.17 [0.90–1.53]

.23

Medical history of heart failure

1.37 [1.04–1.81]

.03

Medical history of COPD

1.21 [0.88–1.63]

.23

Medical history of cancer

0.80 [0.58–1.07]

.14

Hyperpolypharmacy^b

2.02 [1.44–2.88]

< .001

- Louvain

0.72 [0.50–1.02]

.07

- Utrecht

0.69 [0.50–0.95]

.02

- Cork

0.53 [0.37–0.74]

< .001

Medical history of dementia

1.18 [0.75–1.85]

.46

Medical history of depression

1.30 [0.88–1.90]

.17

Medical history of atrial fibrillation

2.01 [1.59–2.55]

< .001

Medical history of coronary heart disease

1.29 [1.01–1.64]

.04

Medical history of cardiac failure

1.79 [1.39–2.30]

< .001

Medical history of chronic renal failure

0.85 [0.65–1.10]

.23

Medical history of bleeding

1.29 [0.93–1.77]

.11

Hyperpolypharmacy^b

1.74 [1.29–2.37]

< .001

ADL

0.95 [0.87–1.03]

.19

- Medical

1.32 [0.90–1.97]

.16